Psoriasis Clinical Trial

Vtama in Psoriasis Patients Being Treated With Biologics.

Summary

Open label study to assess 12 weeks of add-on VTAMA® (tapinarof) Cream, 1% QD in patients with ≥3% BSA who have received biologic therapy for at least 24 weeks.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Male or female adult ≥ 18 years of age;
Diagnosis of chronic plaque-type
Patient with ≥3% BSA
Patient has been treated with biologic for a minimum of 24 weeks
Able and willing to give written informed consent prior to performance of any study-related procedures.

Exclusion Criteria:

≤3% BSA
Patient not receiving biologic agent, or receiving biologic agent <24weeks

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

30

Study ID:

NCT06103695

Recruitment Status:

Completed

Sponsor:

Psoriasis Treatment Center of Central New Jersey

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Schweiger Derm Group
East Windsor New Jersey, 08520, United States

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

30

Study ID:

NCT06103695

Recruitment Status:

Completed

Sponsor:


Psoriasis Treatment Center of Central New Jersey

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.